Literature DB >> 21903766

Ammonia reduction with ornithine phenylacetate restores brain eNOS activity via the DDAH-ADMA pathway in bile duct-ligated cirrhotic rats.

Vairappan Balasubramaniyan1, Gavin Wright, Vikram Sharma, Nathan A Davies, Yalda Sharifi, Abeba Habtesion, Rajeshwar P Mookerjee, Rajiv Jalan.   

Abstract

Ammonia is central in the pathogenesis of hepatic encephalopathy, which is associated with dysfunction of the nitric oxide (NO) signaling pathway. Ornithine phenylacetate (OP) reduces hyperammonemia and brain water in cirrhotic animals. This study aimed to determine whether endothelial NO synthase activity is altered in the brain of cirrhotic animals, whether this is associated with changes in the endogenous inhibitor, asymmetric-dimethylarginine (ADMA) and its regulating enzyme, dimethylarginine-dimethylaminohydrolase (DDAH-1), and whether these abnormalities are restored by ammonia reduction using OP. Sprague-Dawley rats were studied 4-wk after bile duct ligation (BDL) (n = 16) or sham operation (n = 8) and treated with placebo or OP (0.6 g/kg). Arterial ammonia, brain water, TNF-α, plasma, and brain ADMA were measured using standard techniques. NOS activity was measured radiometrically, and protein expression for NOS enzymes, ADMA, DDAH-1, 4-hydroxynonenol ((4)HNE), and NADPH oxidase (NOX)-1 were measured by Western blotting. BDL significantly increased arterial ammonia (P < 0.0001), brain water (P < 0.05), and brain TNF-α (P < 0.01). These were reduced significantly by OP treatment. The estimated eNOS component of constitutive NOS activity was significantly lower (P < 0.05) in BDL rat, and this was significantly attenuated in OP-treated animals. Brain ADMA levels were significantly higher and brain DDAH-1 significantly lower in BDL compared with sham (P < 0.01) and restored toward normal following treatment with OP. Brain (4)HNE and NOX-1 protein expression were significantly increased in BDL rat brain, which were significantly decreased following OP administration. We show a marked abnormality of NO regulation in cirrhotic rat brains, which can be restored by reduction in ammonia concentration using OP.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21903766     DOI: 10.1152/ajpgi.00097.2011

Source DB:  PubMed          Journal:  Am J Physiol Gastrointest Liver Physiol        ISSN: 0193-1857            Impact factor:   4.052


  19 in total

1.  Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis.

Authors:  Avinash Kumar; Gangarao Davuluri; Rafaella Nascimento E Silva; Marielle P K J Engelen; Gabrie A M Ten Have; Richard Prayson; Nicolaas E P Deutz; Srinivasan Dasarathy
Journal:  Hepatology       Date:  2017-04-28       Impact factor: 17.425

Review 2.  Endothelial dysfunction in cirrhosis: Role of inflammation and oxidative stress.

Authors:  Balasubramaniyan Vairappan
Journal:  World J Hepatol       Date:  2015-03-27

Review 3.  Current state of knowledge of hepatic encephalopathy (part I): newer treatment strategies for hyperammonemia in liver failure.

Authors:  Rune Gangsoy Kristiansen
Journal:  Metab Brain Dis       Date:  2016-09-21       Impact factor: 3.584

4.  Abnormal brain oxygen homeostasis in an animal model of liver disease.

Authors:  Anna Hadjihambi; Cristina Cudalbu; Katarzyna Pierzchala; Dunja Simicic; Chris Donnelly; Christos Konstantinou; Nathan Davies; Abeba Habtesion; Alexander V Gourine; Rajiv Jalan; Patrick S Hosford
Journal:  JHEP Rep       Date:  2022-05-24

Review 5.  Ornithine phenylacetate revisited.

Authors:  Maria Jover-Cobos; Lorette Noiret; Yalda Sharifi; Rajiv Jalan
Journal:  Metab Brain Dis       Date:  2013-03-02       Impact factor: 3.584

6.  Asymmetric dimethylarginine is strongly associated with cognitive dysfunction and brain MR spectroscopic abnormalities in cirrhosis.

Authors:  Jasmohan S Bajaj; Vishwadeep Ahluwalia; James B Wade; Arun J Sanyal; Melanie B White; Nicole A Noble; Pamela Monteith; Michael Fuchs; Richard K Sterling; Velimir Luketic; Iliana Bouneva; Richard T Stravitz; Puneet Puri; Kenneth A Kraft; Hochong Gilles; Douglas M Heuman
Journal:  J Hepatol       Date:  2012-08-11       Impact factor: 25.083

7.  Recombinant adenovirus containing hyper-interleukin-6 and hepatocyte growth factor ameliorates acute-on-chronic liver failure in rats.

Authors:  Dan-Dan Gao; Jia Fu; Bo Qin; Wen-Xiang Huang; Chun Yang; Bei Jia
Journal:  World J Gastroenterol       Date:  2016-04-28       Impact factor: 5.742

Review 8.  Glycine and hyperammonemia: potential target for the treatment of hepatic encephalopathy.

Authors:  Rune Gangsøy Kristiansen; Christopher F Rose; Lars Marius Ytrebø
Journal:  Metab Brain Dis       Date:  2016-06-23       Impact factor: 3.584

Review 9.  Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications.

Authors:  Csaba Matyas; György Haskó; Lucas Liaudet; Eszter Trojnar; Pal Pacher
Journal:  Nat Rev Cardiol       Date:  2020-09-30       Impact factor: 32.419

Review 10.  Ammonia toxicity: from head to toe?

Authors:  Srinivasan Dasarathy; Rajeshwar P Mookerjee; Veronika Rackayova; Vinita Rangroo Thrane; Balasubramaniyan Vairappan; Peter Ott; Christopher F Rose
Journal:  Metab Brain Dis       Date:  2016-12-24       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.